

# Financial Tear Sheet

## Corporate Profile

Fibrocell is an autologous cell and gene therapy company translating personalized biologics into medical breakthroughs. Fibrocell's most advanced product candidate, azficel-T, uses its proprietary autologous fibroblast technology and is in a Phase II clinical trial for the treatment of vocal fold scarring resulting in chronic or severe dysphonia. In collaboration with Intrexon Corporation (NYSE:XON), a leader in synthetic biology, Fibrocell is also developing gene therapies for skin and joint diseases using genetically-modified autologous fibroblasts. Fibrocell is in preclinical development of FCX-007, its orphan gene-therapy product candidate, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). Fibrocell is also in preclinical development of FCX-013, its gene-therapy product candidate, for the treatment of linear scleroderma. In addition, Fibrocell and Intrexon will be commencing preclinical development of a gene therapy for the treatment of chronic inflammatory and degenerative diseases of the joint, including arthritis and related conditions

## Stock Information

### FCSC (Common Stock)

<b>Exchange</b>	NASDAQ CM (US Dollar)
<b>Price</b>	<b>\$0.66</b>
<b>Change (%)</b>	<b>▼ 0.04 (5.71%)</b>
<b>Volume</b>	848,230
<b>52 Week Low</b>	\$0.61
<b>Market Cap</b>	\$14,828,969
<b>Rolling EPS</b>	-1.81
<b>PE Ratio</b>	N/A
<b>Shares Outstanding</b>	22,434,143

Data as of 12/15/17 4:00 p.m. ET



## Recent Headlines & Events

12/11/17 - 4:01 p.m.  
Fibrocell Announces Closing of \$10.5 Million Underwritten Public Offering

12/07/17 - 7:01 a.m.  
Fibrocell Announces Pricing of \$10.5 Million Underwritten Public Offering

There are currently no events scheduled.

### SEC Filings

Filing Date	Form
12/13/17	4
12/13/17	SC 13D/A
12/11/17	8-K
12/08/17	424B4

### Corporate Governance

Douglas J. Swirsky	Chairman of the Board
Julian P. Kirk	Director
Marc B. Mazur	Director
John Maslowski	Director
Kelvin D. Moore	Director
Marcus E. Smith	Director
Christine St.Clare	Director

### Ownership Summary

Shareholders				
	Holders	Value (\$MM)	% O/S	Shares
Institution	42	13.40	48.4	10,868,082
Mutual Fund	16	1.94	3.8	856,650
Director and Officer	1	.25	0.5	105,600

\*Insider values reflect direct beneficial ownership.

Top Holders				
	Shares Held	% O/S	Share Change	Filing Date
Third Security, LLC	8,267,413	36.9	2,727,273	12/11/17
MSD Partners, L.P.	692,960	3.1	0	09/30/17
Fidelity Management & Research Company	587,414	2.6	-262,800	09/30/17
The Vanguard Group, Inc.	328,576	1.5	-18,000	09/30/17
Pura Vida Investments, LLC	297,000	1.3	297,000	09/30/17
Renaissance Technologies LLC	118,764	0.5	10,500	09/30/17
Morgan Stanley Wealth Management	82,602	0.4	47,866	09/30/17
Creative Planning, Inc.	61,090	0.3	0	09/30/17
Geode Capital Management, L.L.C.	58,710	0.3	0	09/30/17
Parametric Portfolio Associates LLC	48,259	0.2	0	09/30/17

Data provided by Nasdaq. Minimum 15 minutes delayed.